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EDITORIAL
Combining precision medicine and prophylaxis in oesophageal
squamous cell carcinoma
A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive
chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to
identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine
strategies in ESCC.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01057-3
MAIN
Oesophageal cancer comprises two main histological subtypes,
oesophageal adenocarcinoma (OAC) and oesophageal squamous
cell carcinoma (ESCC). ESCC is the most common subtype globally,
and aetiological factors include tobacco, alcohol, specific dietary
practices, and social deprivation.1 ESCC is an aggressive disease
with 5-year overall survival (OS) of ~15%.1 The extensive
oesophageal submucosal lymphatic plexus facilitates early dis-
semination of ESCC to regional lymph nodes and the majority of
patients have micrometastatic or disseminated disease at the time
of initial presentation.1
Definitive concurrent chemoradiotherapy (dCRT) is one standard
of care for ESCC patients with loco-regionally confined disease with
reported survival comparable to oesophagectomy and lymphade-
nectomy in randomised studies.1 However, loco-regional tumour
persistence or recurrence, which is difficult to palliate, occurs in the
majority and distant metastases in about half of dCRT-treated
patients.1–4 To improve dCRT outcomes, approaches that combine
better loco-regional tumour control with more effective systemic
treatment of micrometastatic disease are required.
In this issue of the British Journal of Cancer, Xie et al.5 report a
Phase 3 randomised controlled trial (RCT) with a 2 × 2 factorial
design investigating whether prophylactic elective nodal irradia-
tion (ENI) dCRT is superior to conventional field irradiation (CFI)
and whether dCRT plus the epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) erlotinib, is superior to dCRT
alone. ENI includes the uninvolved lymph nodes in the treatment
field, which are at risk for micrometastatic disease, while CFI
includes only the metastatic nodes. Several retrospective studies
of dCRT with ENI in ESCC have reported reduced loco-regional
failure, but some concerns remain regarding increased toxicity.
EGFR has an established role in ESCC pathogenesis and EGFR
inhibitors can reverse the radioresistance of oesophageal cancer
cells. In this article,5 the authors provide a follow-up report on
long-term outcomes, and importantly the results of a predictive
biomarker analysis. They show that the early outcome benefits for
ENI and erlotinib have been sustained. Key findings are that ENI
improves OS compared to CFI (median OS, 38.5 vs. 22.6 months;
hazard ratio [HR], 0.74; P= 0.018), and the addition of erlotinib
also improves OS (median OS, 39.4 vs. 27.4 months; HR, 0.75; P=
0.025). The reported 5-year survival of 19.6% for CFI dCRT without
erlotinib is entirely consistent with expectations, while 5-year OS
of 44.9% for prophylactic ENI dCRT plus erlotinib represents an
impressive incremental gain. Importantly, Xie et al.5 also provide
reassurance regarding the late toxicity of ENI (plus erlotinib).
This is the first large RCT comparing ENI and CFI in ESCC and
provides valuable data in this regard. The addition of anti-EGFR
treatments to dCRT with CFI has been evaluated in previous RCTs,
which demonstrated no benefit.2–4 The results presented here
contrast with those from these earlier studies, which enrolled both
OAC and ESCC and involved evaluation of the EGFR monoclonal
antibody, cetuximab. In SCOPE-1, the addition of cetuximab to
dCRT resulted in worse OS.2 In SAKK75/08, and RTOG 0436, OS was
not improved with cetuximab, but in SAKK75/08, the addition of
cetuximab did improve loco-regional control.3,4 Similarly, in
biomarker unselected advanced ESCC patients, panitumumab
added to cisplatin plus fluorouracil did not improve OS.6 Based on
the findings of these studies and others, some consider that,
despite strong evidence of its pathogenic role, EGFR is not a useful
target for ESCC and OAC. However, this ignores consistent
observations that, in biomarker-selected patients, anti-EGFR
therapies in ESCC and OAC demonstrate efficacy.7,8 These studies
demonstrate the predictive impact of EGFR gene copy number
gain (CNG), or high EGFR protein expression.7,8 The new findings
presented by Xie et al.5 extend this important observation,
demonstrating that only patients with high EGFR expression
(immunohistochemical [IHC] score +2, +3) appear to benefit from
the addition of erlotinib to dCRT (median OS in erlotinib treated
for EGFR IHC +2/3 vs. 0/+1, is 46.5 vs. 9.5 months; P= 0.007). The
magnitude of benefit is striking. Taken together, these trials
suggest therapeutic value for anti-EGFR treatments in ESCC that
are EGFR IHC and/or EGFR CNG positive. However, even with
appropriate biomarker selection, clinical resistance to anti-EGFR
monotherapy in advanced stage ESCC (and OAC) often emerges
rapidly,7,8 which suggests that combination treatments with EGFR
inhibitors are likely to be important for meaningful clinical benefit
—in this context, the positive findings by Xie et al.5 with erlotinib
added to dCRT take on greater significance.
Recent positive findings for immune checkpoint inhibitors (ICIs)
in advanced ESCC have understandably focussed attention on
targeting PD-L1/PD-1.9 However, only a minority subgroup of
patients respond to ICIs and in squamous cell carcinomas (SCCs),
including ESCC, EGFR activation is associated with depleted
tumour-infiltrating lymphocytes, resistance to ICI, and possibly
hyper-progression.10 This suggests that precise targeting of EGFR-
driven ESCC should remain an important therapeutic aim.
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A key strength of the Xie et al.5 study is that it enrolled only ESCC.
This is important in context of results of genomic landscaping
studies, which indicate that ESCC has more similarity to SCC from
other sites, than it does to OAC.11 Common genomic aberrations can
be seen in SCCs when analysed at a pathway level, and targeting
EGFR is perhaps best viewed in this context of emerging precision
medicine targets and strategies for ESCC (Fig. 1).
A key limitation of this study5 includes the assessment of EGFR in
only a minority subset, albeit one that was representative of the
whole trial cohort. Prospective validation of EGFR IHC and/or EGFR
CNG as a predictive biomarker is therefore needed. Also, the radiation
dose of 60 Gy used is not widely practiced outside China and Japan,
which will be a concern for many radiation oncologists, and makes
the case for additional RCTs in western and other populations with
more typically used radical radiation doses of 50–50.4 Gy.
Overall, the authors should be congratulated on completing a
study that has efficiently addressed two important clinical
questions for ESCC, and provided a signal that the combination
of a precision medicine (erlotinib in EGFR IHC high) and
prophylaxis (ENI) can provide very meaningful incremental
survival benefit in ESCC. Considering the high unmet clinical
need and the paucity of targets for precision treatments in ESCC,
those such as EGFR for which we do see signals should be
investigated comprehensively.
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Fig. 1 Emerging strategies and targets for ESCC precision medicine. IHC immunohistochemistry, ICI immune checkpoint inhibitor, PD-L1
programmed death-ligand 1, RTK receptor tyrosine kinase, DDRD DNA damage response deficient, CTx chemotherapy, CNG copy number
gain, CNL copy number loss, EGFR epidermal growth factor receptor, PI3K phosphoinositide 3-kinase, mut mutant, NRF2 nuclear factor,
erythroid 2 like 2, CDK cyclin-dependent kinase, PARPi poly(ADR-ribose) polymerase inhibitor, FGFRi fibroblast growth factor receptor
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